Table A.2.
Demographic and baseline clinical characteristics of first-line therapy.
| Demographic characteristics | First-line therapy |
||||
|---|---|---|---|---|---|
| With PN |
Without PN |
p value | |||
|
n = 1267 |
n = 2687 |
||||
| n/mean | %/SD | n/mean | %/SD | ||
| Age (mean, SD) | 64.0 | 10.81 | 64.2 | 11.61 | 0.661 |
| Age group (n, %) | |||||
| 18–34 | 4 | 0.3% | 9 | 0.3% | 1.000 |
| 35–44 | 36 | 2.8% | 95 | 3.5% | 0.255 |
| 45–54 | 204 | 16.1% | 429 | 16.0% | 0.914 |
| 55–64 | 459 | 36.2% | 1021 | 38.0% | 0.283 |
| 65–74 | 333 | 26.3% | 555 | 20.7% | 0.000 |
| 75+ | 231 | 18.2% | 578 | 21.5% | 0.017 |
| Sex (n, %) | |||||
| Male | 761 | 60.1% | 1621 | 60.3% | 0.874 |
| Female | 506 | 39.9% | 1066 | 39.7% | 0.874 |
| Payer (n, %) | |||||
| Commercial | 690 | 54.5% | 1536 | 57.2% | 0.110 |
| Medicare | 577 | 45.5% | 1151 | 42.8% | 0.110 |
| Insurance plan type (n, %) | |||||
| Comprehensive | 259 | 20.4% | 503 | 18.7% | 0.200 |
| Exclusive-provider organization | 4 | 0.3% | 19 | 0.7% | 0.131 |
| Health-maintenance organization | 141 | 11.1% | 321 | 11.9% | 0.455 |
| Point of service (POS) | 66 | 5.2% | 147 | 5.5% | 0.734 |
| Preferred-provider organization | 704 | 55.6% | 1508 | 56.1% | 0.742 |
| POS with capitation | 8 | 0.6% | 14 | 0.5% | 0.663 |
| Consumer-driven healthplan | 60 | 4.7% | 116 | 4.3% | 0.552 |
| High-deductible healthplan | 25 | 2.0% | 59 | 2.2% | 0.651 |
| Unknown | 0 | 0.0% | 0 | 0.0% | |
| Geographic region (n, %) | |||||
| Northeast | 217 | 17.1% | 488 | 18.2% | 0.428 |
| North central | 372 | 29.4% | 744 | 27.7% | 0.276 |
| South | 448 | 35.4% | 1011 | 37.6% | 0.168 |
| West | 221 | 17.4% | 410 | 15.3% | 0.080 |
| Unknown | 9 | 0.7% | 34 | 1.3% | 0.116 |
| Population density (n, %) | |||||
| Urban | 1086 | 85.7% | 2276 | 84.7% | 0.406 |
| Rural | 172 | 13.6% | 379 | 14.1% | 0.654 |
| Unknown | 9 | 0.7% | 32 | 1.2% | 0.164 |
| Duration of line of therapy (mean, SD) | 234.9 | 219.9 | 244.6 | 241.2 | 0.222 |
| DCI (mean, SD) | 4.5 | 2.84 | 4.5 | 2.86 | 0.581 |
| DCI (n, %) | |||||
| 0 | 11 | 0.9% | 21 | 0.8% | 0.777 |
| 1 | 12 | 0.9% | 13 | 0.5% | 0.086 |
| 2 | 402 | 31.7% | 900 | 33.5% | 0.270 |
| 3+ | 842 | 66.5% | 1753 | 65.2% | 0.452 |
| DCI components (n, %) | |||||
| Myocardial infarction | 46 | 3.6% | 87 | 3.2% | 0.523 |
| Congestive heart failure | 100 | 7.9% | 217 | 8.1% | 0.843 |
| Peripheral vascular disease | 53 | 4.2% | 112 | 4.2% | 0.983 |
| Cerebrovascular disease | 87 | 6.9% | 179 | 6.7% | 0.810 |
| Dementia | 2 | 0.2% | 7 | 0.3% | 0.727 |
| Chronic pulmonary disease | 206 | 16.3% | 417 | 15.5% | 0.551 |
| Rheumatologic disease | 30 | 2.4% | 60 | 2.2% | 0.791 |
| Peptic ulcer disease | 19 | 1.5% | 50 | 1.9% | 0.418 |
| Mild liver disease | 10 | 0.8% | 15 | 0.6% | 0.392 |
| Diabetes (mild to moderate) | 286 | 22.6% | 561 | 20.9% | 0.225 |
| Diabetes with chronic complications | 93 | 7.3% | 144 | 5.4% | 0.014 |
| Hemiplegia or paraplegia | 5 | 0.4% | 11 | 0.4% | 0.946 |
| Renal disease | 285 | 22.5% | 573 | 21.3% | 0.405 |
| Moderate or severe liver disease | 2 | 0.2% | 5 | 0.2% | 1.000 |
| Human immunodeficiency virus | 3 | 0.2% | 6 | 0.2% | 1.000 |
| Any malignancy, including lymphoma and leukemia | 1094 | 86.3% | 2339 | 87.0% | 0.542 |
| Metastatic solid tumor | 190 | 15.0% | 417 | 15.5% | 0.670 |
| Prior primary cancer (n, %) | |||||
| Solid tumor | 309 | 24.4% | 647 | 24.1% | 0.832 |
| Hematologic cancer | 157 | 12.4% | 363 | 13.5% | 0.332 |
| Preperiod events of interest (n, %) | |||||
| Chronic kidney disease | 243 | 19.2% | 503 | 18.7% | 0.730 |
| End-stage renal disease/renal failure | 84 | 6.6% | 170 | 6.3% | 0.717 |
| Skeletal-related events | 610 | 48.1% | 1303 | 48.5% | 0.838 |
| Hypercalcemia | 172 | 13.6% | 361 | 13.4% | 0.904 |
| Venous thromboembolism | 52 | 4.1% | 120 | 4.5% | 0.603 |
| Neutropenia | 42 | 3.3% | 93 | 3.5% | 0.813 |
| Pneumonia | 123 | 9.7% | 251 | 9.3% | 0.713 |
| Major bleeding | 26 | 2.1% | 52 | 1.9% | 0.805 |
| GI bleeding | 63 | 5.0% | 141 | 5.2% | 0.715 |
| Anemia | 718 | 56.7% | 1504 | 56.0% | 0.681 |
| Anemia or anemia treatment | 720 | 56.8% | 1514 | 56.3% | 0.776 |
| Thrombocytopenia | 95 | 7.5% | 188 | 7.0% | 0.568 |
| Amyloidosis | 49 | 3.9% | 88 | 3.3% | 0.342 |
DCI, Deyo–Charlson Comorbidity Index; GI, gastrointestinal; PN, peripheral neuropathy; SD, standard deviation.